SOLACI | Latin American Society of Interventional Cardiology
PDF) Switching Ticagrelor to 600 mg or 300 mg Clopidogrel Loading Bridge in Patients with Unstable Angina
Ticagrelor plus aspirin versus clopidogrel plus aspirin for platelet reactivity in patients with minor stroke or transient ischaemic attack: open label, blinded endpoint, randomised controlled phase II trial | The BMJ
International Expert Consensus on Switching Platelet P2Y<sub>12</sub> Receptorâ•fiInhibiting Therapies
How to Switch from Clopidogrel to Prasugrel or Ticagrelor - ppt download
Frontiers | Prevalence of adverse events during ticagrelor versus clopidogrel treatment and its association with premature discontinuation of dual antiplatelet therapy in East Asian patients with acute coronary syndrome
JCM | Free Full-Text | Switching Ticagrelor to 600 mg or 300 mg Clopidogrel Loading Bridge in Patients with Unstable Angina
Switching between oral... - البورد العراقي للصيدلة السريرية | Facebook
JCM | Free Full-Text | Switching Ticagrelor to 600 mg or 300 mg Clopidogrel Loading Bridge in Patients with Unstable Angina
How to Switch from Clopidogrel to Prasugrel or Ticagrelor - ppt download
Pharmacodynamic profiles of switching from ticagrelor to clopidogrel... | Download Scientific Diagram
Escalating P2Y 12 inhibiting therapy (switching from clopidogrel to... | Download Scientific Diagram
Switching between P2Y12 inhibitors: Rationale, methods, and expected consequences - ScienceDirect
Dr. Sheila Sahni on X: "Algorithm for switching between oral P2Y12 inhibitors in the acute and chronic setting. (For the Figure: LD = loading dose; MD = maintenance dose) Source: 2017 ESC
Dual Antiplatelet and Glycoprotein Inhibitors in Emergency PCI | SpringerLink
Journal of Invasive Cardiology - An acute antiplatelet-switching strategy: Using prasugrel or ticagrelor for rapid and reliable periprocedural antiplatelet action, followed by a switch to clopidogrel -- The SWITCH Study Antoine E.
Half‐Dose (45 mg Twice Daily) Ticagrelor Versus Clopidogrel in Neuroendovascular Dual Antiplatelet Therapy: A Single‐Center Cohort Study | Stroke: Vascular and Interventional Neurology
Editor's Corner | DAPT, Our Genome and Clopidogrel "Resistance": Are We Near an Answer to "Which Drug, When?" - American College of Cardiology
Fernando de la Guía on X: "Algorithm for switching between oral P2Y12 inhibitors In the acute and chronic setting #ESCCongress @escardio https://t.co/JWK126ejsx" / X
![PDF] De-escalation therapy after acute coronary syndrome: is it reasonable to switch from prasugrel (or ticagrelor) to clopidogrel early? | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/9821495c3b180b474079b1b8e98cc52218703a27/4-Figure1-1.png "PDF] De-escalation therapy after acute coronary syndrome: is it reasonable to switch from prasugrel (or ticagrelor) to clopidogrel early? | Semantic Scholar")
PDF] De-escalation therapy after acute coronary syndrome: is it reasonable to switch from prasugrel (or ticagrelor) to clopidogrel early? | Semantic Scholar
Clopidogrel and ticagrelor co-therapy resulted in more patients... | Download Scientific Diagram
Effectiveness and Safety of Ticagrelor Implementation in Patients with Acute Coronary Syndrome undergoing Percutaneous Coronary Intervention: A Cohort Study in Western Denmark - The Lancet Regional Health – Europe
JCM | Free Full-Text | Switching Ticagrelor to 600 mg or 300 mg Clopidogrel Loading Bridge in Patients with Unstable Angina
Pharmacodynamic profiles of switching from ticagrelor to clopidogrel... | Download Scientific Diagram
Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial - The Lancet
Escalation and De-escalation Strategy for DAPT: Rationale and Evidence
Switching P2Y12-receptor inhibitors in patients with coronary artery disease | Nature Reviews Cardiology
